Det er ikke vores erfaring, at prisforskenen
mellem t!llr-glas og glas indeholdende antikoagul–
ans er ubetydelig. Hvis man vii anvende glas in–
deholdende antikoagulans, er man tvunget til at
anvende disse glas til alle pr!llver inklusive rutine–
pr!llver og pr!llver indsendt fra almen praksis for at
kunne sammenligne resultater, jvf. ovenstående,
men naturligvis i srerlig grad resultater fra kalium
analysen. Dette vil efter vores opfattelse give en
betydelig ekstra omkostning for laboratoriet.
Fordelen ved thrombin-glasset er, at det kun er
n!lldvendigt at anvendedet til haste analyser,mens
det traditionelle t!llr-glas anvendes til rutinepr!llver.
Hervedmillimeres omkostningerne,med den for–
del at sammekorte svartid kan opnås som ved an–
vendelse af plasma.
Referencer
l . Lande, K. Plasma bedre enn serum til rutineanaly–
ser?Klinisk Kemi i Norden 1997; 911:25.
2. Donelly JG et al. Is heparinized plasma suitable for
use in routine biochernistry? Ped Path Lab Med 1995;
15: 555-559.
3. Jämförande studie av prov taget
i
SST-rör resp. rör
med tillsats av trombin.Utförd vidAvdelingen för Kli–
niskKemi Länssjukhuset iHalmstad avAvdelingsföre–
ståndare Lena Johansson. Kan rekvireres hos Becton
Dickinson, Sdr. Ringvej 39, DK-2605 Brs>lndby.
4. AfprS'lvning af Thrombin-glas fra Becton Dickinson
til brug ved analyse påVitrosChernistrySystems.Gen–
nernfS'lrt i samarbejde mellem danske Vitros brugere.
Danmark 1996. Kan rekvireres hos Becton Dickinson,
Sdr. Ringvej 39, DK-2605 Brs>lndby.
Produktnyt
Ansvarig: PalleWang, Odense, fax +45 65 4119 11
The First International BayerDiagnostics
Central Laboratory Symposium on Internet
Until the end of 1997 the presentations of main
speakers from the first International Bayer
Diagnostics Central Laboratory Symposium in
Rome, April 20-22 are featured online at
topicsareAnernia
andWorkflowManagement, but additional topics
inhematology and immunochernistry are featured
includingpresentations from alpha site evaluators
ofBayersnewhematology system,ADVIATM120
andnew informationonBayerImmuno ITM assays
andworkflow impact.
CHr™ a New FDAApprovedAssay to
CombatAnemia
Bayer announces the CHr™ assay (Reticulocyte
The lower cost and convenience associated with
the new CHr™ assay make it practical to use
routinely toobtain critical datawhen assessing and
adjusting treatments foranernia patients.Using the
CHr™ assay, physicians can treat functional iron
deficiency more successfully by stabilizing the
delicate balancebetween erythropoietin (rHuEPO)
and iron therapies tooptirnize redblood cell (RBC)
production. The new CHr™assay is avai1able on
Technicon H*3 RTX and RTC hematology
analyzers and will be available on Bayers new
hematology system,ADVIA™ 120.
For further information please contact:
Hemoglobin Content) enabling health care Bayer
NS,
Denmark
professionals to improve treatment of anemia BayerAS, Norway
through direct measurement of hemoglobin in BayerAB, Sweden
newly produced red blood cells, or reticulocytes. Bayer OY, Finland
Phone:
+
45 45 23 50 00
Phone:
+
47 67 06 86 00
Phone:
+
46 31 83 98 00
Phone:
+
35 89 88 78 87
Klinisk Kemi
i
Norden
2,
1997
69
